BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Regulus Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:32 pm Purchase | 2024-09-30 | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 883,844 1.300% | 883,844 (New Position) | Filing |